Head-To-Head Contrast: Adaptimmune Therapeutics PLC (ADAP) vs. Its Competitors
Adaptimmune Therapeutics PLC (NASDAQ: ADAP) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Adaptimmune Therapeutics PLC to similar companies based on the strength of its risk, profitability, valuation, dividends, analyst recommendations, earnings and institutional ownership.
This is a summary of current ratings and target prices for Adaptimmune Therapeutics PLC and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Adaptimmune Therapeutics PLC||0||1||3||0||2.75|
|Adaptimmune Therapeutics PLC Competitors||808||3174||11492||230||2.71|
Valuation & Earnings
This table compares Adaptimmune Therapeutics PLC and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Adaptimmune Therapeutics PLC||$14.20 million||-$71.57 million||-10.67|
|Adaptimmune Therapeutics PLC Competitors||$286.20 million||$34.74 million||145.40|
Adaptimmune Therapeutics PLC’s competitors have higher revenue and earnings than Adaptimmune Therapeutics PLC. Adaptimmune Therapeutics PLC is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Adaptimmune Therapeutics PLC has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics PLC’s competitors have a beta of 6.02, meaning that their average share price is 502% more volatile than the S&P 500.
Institutional and Insider Ownership
67.9% of Adaptimmune Therapeutics PLC shares are owned by institutional investors. Comparatively, 48.9% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 24.5% of Adaptimmune Therapeutics PLC shares are owned by insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Adaptimmune Therapeutics PLC and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Adaptimmune Therapeutics PLC||-138.46%||-27.99%||-21.47%|
|Adaptimmune Therapeutics PLC Competitors||-5,371.53%||-435.64%||-41.05%|
Adaptimmune Therapeutics PLC beats its competitors on 8 of the 12 factors compared.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.
Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.